This suggests the VEGFR2-targeted QDs demonstrated excellent imaging capabilities, providing enhanced contrast and improved visualization of CRC lesions compared to non-targeted QDs or conventional imaging agents [61]. This evidence concerns the gene KDR and colorectal carcinoma.